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INTRODUCTION 
Gliclazide(GCZ) is a specific type of an anti-diabetic 
drug most commonly used fortype2 diabetes 
mellitus.1Chemically it is 1-(1-azabicyclo(3,3,0) 
octyl)-3-p-tolylsulphonylurea2. Literature review 
revealed very few analytical methods 
includingRadioimmunoassay3, Gas chromatography4, 
HPLC5,6 Evaporative Light Scattering 
Detection7,LC-MS8and Mass spectroscopy9 for 
quantification of GCZ in pharmaceutical dosage forms. 
In the present work, a rapid FTIR spectroscopic 
method10,11 has been developed for the estimation of 
GCZ in bulk drug and pharmaceutical dosage form. To 
develop the quantitative analysis method, a standard 
solution of known concentration is prepared and spectra 
are collected from aliquots of the standard. Specified 
absorption band is identified and the peak area is 
calculated. 
MATERIALS AND METHODS 
Instrument 
All spectral and absorbance measurements were made 
on FTIR-Model ABB MB 3000. 
Standard solution of GCZ 
A 1mg/ml stock solution of GCZ was prepared by 
dissolving 50mg of drug in 50ml of methanol. 
Sample preparation 
Twenty tablets were weighed. A quantity equivalent to 
50mg of GCZ was weighed accurately, transferred to a 
beaker, dissolved in methanol, filtered through 
whatmann filter paper No.1 into a 50ml volumetric 
flask and made up to volume with methanol to get a 
concentration of 1mg/ml. 
Method 
The stock solution was diluted suitably with methanol 
to give a series of concentration ranging from 
4-24µg/ml of GCZ. The IR spectrum was recorded for 
the various concentrations. The absorbance of the band 
due to amide stretching at 3317cm-1 was measured. The 
IR spectra for GCZ are shown in fig-1. The calibration 
curve of GCZ was obtained by plotting the peak area 
(Amide stretchingcentered at 3317cm-1) versus 
concentration. 
Sample analysis 
Pharmaceutical formulation of GCZ was successfully 
analyzed by the proposed method. Appropriate aliquots 
were subjected to the above method and the amount of 
GCZ was determined. 
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ABSTRACT 
A rapid FTIR spectroscopic method has been proposed for the estimation of Gliclazide in bulk drug and pharmaceutical dosage 
form. The method involves the measurement of the area of the infrared band corresponding to the amide stretching centered at 
3317cm-1. The excipients in the commercial tablet preparation did not interfere with the assay. The linearity range was found to 
be 4-24µg/ml. The technique is reliable and useful for quality control for monitoring the adulteration of pure drug. The proposed 
method is statistically validated and found to be useful for the routine determination of gliclazide in tablets. 
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Fig 1: IR spectrum of GCZ 
 
RESULTS AND DISCUSSION  
The proposed method is statistically validated and found 
to be useful for the routine determination of GCZ in 
tablets. The regressions characteristics like slope  (m), 
intercept(c), correlation coefficient(r), percent relative 
standard deviation (%RSD) and standard error (SE) were 
calculated and the results are summarized in Table-1. All 
validation parameters were found to be highly 
satisfactory. The results of sample analysis showed that 
the drug determined by the proposed method was in good 
agreement with the label claim proving the accuracy of 
the proposed method.        
To study the accuracy and reproducibility of the proposed 
method, recovery experiments were carried out by adding 
a known amount of drug to pre-analyzed sample and the 
percentage recovery calculated.The results are furnished 
in Table-2. The results indicate that there is no 
interference of other ingredient present in the formulation. 
Thus the proposed method is rapid, sensitive, accurate and 
reproducible and useful for the routine determination of 
GCZ in bulk drug and its pharmaceutical dosage form.  
Table1: Statistical parameters 
Parameters Results 
Linearity range(µg/ml) 4-24 
Correlation coefficient (r) 0.9989 
Standard deviation 0.1965 
Standard error 0.0878 
   %RSD 0.4928 
Regression equation                       
y=mx+c 
0.2825x+0.1793 
Intercept 0.1793 
Slope 0.2825 
LOD (µg/ml) 2 
LOQ(µg/ml) 4 
 
Table2: Assay and recovery of GCZ in dosage form 
        Drug Labelled amount(mg) Amount present (mg)* Percentage recovery* 
Gliclazide          40       39.87       100.03 
*Average of 6 determinations 
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